HPTN 084 Update: Long-Acting Injectable CAB vs Daily Oral TDF/FTC for HIV PrEP in Cisgender Women

Source: CCO Official Conference Coverage: Clinical Impact of New HIV Data From AIDS 2022
Download Slideset
July 29-August 2, 2022; Montreal, Quebec
An additional 1 year of unblinded follow-up of the HPTN 084 study continues to support superiority of long-acting injectable CAB vs daily oral TDF/FTC in reducing incident HIV infection among cisgender women at high risk.
Format: Microsoft PowerPoint (.ppt)
File Size: 298 KB
Released: August 3, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings